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Responding to drug driving in Europe
Many of the accidents and deaths that 
occur on European roads are caused 
by drivers whose performance is 
impaired by a psychoactive substance. 
Alcohol alone is estimated to account 
for up to 10 000 road deaths a year 
in the European Union, one quarter of 
all road deaths. No comparable 
figures are available for road 
accidents related to illicit drugs and 
psychoactive medicines, though these 
have been receiving increasing 
attention over the past decade. 
Studies on the effects of psychoactive 
substances on driving performance 
suggest that while both illicit and 
therapeutic drugs can affect driving, 
the effects and their extent can vary 
greatly from substance to substance. 
The latest research suggests that 
cannabis can reduce performance 
and benzodiazepines are generally 
impairing; of the opioids, heroin can 
impair severely, methadone less so, 
and buprenorphine even less. The 
data for stimulant drugs such as 
cocaine, amphetamines and ecstasy 
are more mixed, but suggest that high 
doses are associated with impairment. 
Yet, an objective measure for 
impairment for each drug, similar to the 
blood alcohol concentration, remains 
elusive. 
The complex issue of drug driving is 
currently being investigated by DRUID, 
a major EU project that began in 
2006 and will continue until 2010. 
DRUID aims to provide a solid basis for 
harmonised, EU-wide regulations for 
driving under the influence of alcohol, 
drugs and medicine. 
Until then, this policy briefing 
summarises the key issues facing 
policymakers and describes 
developments across Europe that may 
assist decision-making on the topic.  
Key issues at a glance
1. Reports of drug driving incidents often receive much media 
attention. But, few countries have reliable statistics on the 
prevalence of driving under the influence of drugs. 
4. Various psychoactive medicines, which might or might not be 
legally prescribed and consumed, can impair driving skills.
2. Obtaining sound scientific evidence on behavioural effects, 
prevalence and accident risk is difficult with the available 
data. Many of the studies have small samples and it is 
often difficult to generalise from their results.
5. Currently, police experience considerable difficulty with  
the accurate and rapid identification of drug driving at the 
roadside.  
3. Reflecting the scientific debate about the precise  
effects of the substances, the legal definition of the offence 
of driving under the influence of drugs differs among  
EU Member States. 
6. The effectiveness of information campaigns to prevent drug 
driving is open to question. Key audiences may not be hearing 
the message, or they may be ignoring it.
Definition  
Driving under the influence: Depending on the country’s laws, this may refer to a driver who has: a measured 
reduction of cognitive or psychomotor skills, impulsivity; or more than a defined amount of drug in the blood, expected to 
produce such effects at that level; or any trace of drugs in the blood. 
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Reducing the loss of life caused by 
driving under the influence of 
psychoactive substances requires 
measures that are based on a 
scientific understanding of this 
complex phenomenon. The 
challenge to legislators is to 
design sound and effective laws 
that can be enforced, and that 
give a clear message to the 
public.
Wolfgang Götz,  
EMCDDA Director
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Extent of drug driving  1. 
is not studied in many 
European countries
Studies on drug prevalence in drivers 
published between 1999 and 2007 
provide data for only 13 of the 
27 EU Member States and Norway.
Random roadside surveys of drivers, which 
can give a representative picture of the 
entire driving population, are available for 
three EU Member States and Norway. 
Other surveys provide data on drug use 
among specific subsets of drivers. While 
some studies considered only drivers 
involved in fatal accidents, others looked 
at sample groups of injured drivers, killed 
drivers, drivers involved in accidents, and 
drivers suspected of driving under the 
influence of alcohol or drugs. However, 
the results of these various studies are not 
scientifically comparable. 
Generally, cannabis is the most common 
illicit substance detected, and 
benzodiazepines are the most commonly 
reported psychoactive medicines. Overall, 
the evidence points to much higher 
prevalences of both illicit and prescription 
drugs, often in combination with alcohol, 
among drivers involved in accidents or 
suspected of driving under the influence of 
drugs or alcohol.
The overall scarcity of information 
continues despite a recommendation 
made in 2002 by the European 
Commission’s expert working group on 
drugs, medicines and driving that all 
drivers involved in a fatal accident should 
be tested for alcohol and drug use. 
Barriers to building up 2. 
scientific evidence
More than 30 studies on the prevalence 
of drugs among drivers have been carried 
out across Europe since 1999. However, 
these studies have used various methods 
and sampled different groups of drivers, 
making it difficult to draw overall 
conclusions. 
The number of people sampled has 
ranged from under 50 to over 10 000, 
with more than one third of the studies 
reporting on fewer than 500 individuals. 
National legislation or policies may also 
limit the scope and comparability of 
prevalence studies. For example, random 
roadside tests for drugs are not permitted 
in most countries. In some countries, tests 
are only carried out for illicit drugs, and 
the prevalence of psychoactive medicines 
cannot be ascertained.
A positive test for alcohol may override 
any requirement for drug testing, with 
resource limitations and prosecution 
requirements taking priority over any need 
for comprehensive data gathering. This 
has been the case in Denmark, Estonia, 
Ireland and Portugal. The French SAM 
study, one of the most extensive studies in 
recent years on the subject, was made 
possible by a change to the national 
Road Code obliging the police, in defined 
circumstances, to test all drivers for drugs. 
New international guidance for 
standardisation of study designs have 
been drawn up with the assistance of the 
EMCDDA and the European 
Commission’s DG Transport. It takes into 
account differences between countries’ 
legislation and testing policies, providing 
over a hundred recommendations 
subdivided into the areas of behaviour, 
epidemiology, and toxicology. 
Where to draw  3. 
the line — or lines?
Most European countries take one of two 
approaches to defining the offence of 
driving under the influence of drugs. 
Eleven countries only penalise impaired 
driving, whether caused by illicit drugs or 
medicines. Eleven other countries have 
adopted a ‘zero-tolerance’ policy, 
penalising any driving after drug-taking. In 
seven countries, these two approaches 
are combined in a tiered response to drug 
driving offenders. 
Some ‘zero-tolerance’ countries make no 
distinction between psychoactive 
medicines and illicit drugs, others do. In 
Finland and Sweden, new zero-tolerance 
laws for illicit drugs were passed following 
the experience that the offence of 
impaired driving was extremely difficult to 
prove. In Cyprus, this problem is 
addressed by prosecuting such drivers for 
illegal consumption of drugs. However, 
Belgium and the United Kingdom 
specifically prohibit use of a test result for 
drug driving as evidence for any other 
offence.
Evidence of drug-taking may be detected 
in different biological samples, including 
blood, urine, saliva, sweat and even hair. 
Blood is the ideal matrix for legal proof of 
impairment, but roadside screening by 
oral fluid (saliva) is desirable for 
convenience. Threshold levels for the 
drugs may be set at the lower limit of 
detection, or at levels where impairment 
may be expected to start. However, while 
some drugs, including cannabis and 
opioids, appear to have a dose-
dependent impairing effect, others such as 
amphetamines do not. Tolerance and 
interactions with alcohol or other drugs 
complicate calculations further. In France, 
drivers found combining drugs with 
alcohol receive a higher penalty.
Responding to 4. 
psychoactive medicines
Psychoactive medicines, such as 
painkillers (opioids), sedatives 
(benzodiazepines), antidepressants and 
antihistamines can have sometimes 
considerable effects on the capabilities of 
drivers. Results from studies suggest that 
drivers may be using these drugs either for 
medical reasons following prescription, or 
misusing them, sometimes together with 
illicit substances. Concern is also growing 
about the possible impact of the 
increasing numbers of drug users receiving 
opioid substitution treatment.
Most countries’ laws penalise impairment 
from any drug, whether illicit or medicinal. 
In France, Austria and Portugal, some 
impairing psychoactive medicines such as 
benzodiazepines are not covered by the 
drug driving law, though they may be 
covered by a general offence such as 
dangerous driving. In contrast, laws in the 
Czech Republic, Estonia, Poland, Slovenia 
and Slovakia penalise driving with any 
trace of a substance, even if medicinal. 
Seven countries (Belgium, Czech 
Republic, Germany, Latvia, Luxembourg, 
Slovakia, Finland) have adopted a 
two-stage system that penalises any trace 
of an illicit substance with a non-criminal 
or lower-level criminal fine, but more 
severely penalises impairment by any 
substance. In Latvia, impairment by a 
medicinal substance will incur a lower fine 
than any trace of an illicit substance. In 
Finland and Sweden, drivers found with 
medicines may be exempted from charge 
if they can provide a medical prescription, 
though they may still be charged if their 
driving was judged impaired.
Testing for drug driving 5. 
After stopping a driver, the police officer 
may need to perform an initial screening 
for drug use, by analysing behaviour or 
biological samples. In February 2002, the 
European Commission expert working 
group on drugs, medicines and driving 
recommended that police involved in 
traffic control receive mandatory training 
in recognising the signs of impairment due 
to drugs. These tests may include, for 
example, examination of the size of the 
pupils, coordination tests, behavioural 
tests, reactions and manner of speaking. 
Yet by 2007, only four EU countries 
(Belgium, Portugal, Sweden, United 
Kingdom) reported obligatory training 
in this area for traffic police, while 
11 reported some ad hoc training. 
Furthermore, the tests are not the same in 
each country.
Oral fluid (saliva) might be acceptable for 
roadside screening of drivers — urine is not 
appropriate to indicate impairment. The 
reliability of devices for roadside saliva 
testing, however, has yet to be confirmed. 
Of the nine on-site saliva-testing devices 
evaluated by the EU’s Rosita-2 project 
between 2003 and 2005, not one could 
be recommended for roadside screening 
of drivers. The limitations of the devices 
might be compensated to some extent by 
modifying the testing protocol. Since 
2004, a system in Victoria, Australia uses 
two saliva tests in series at the roadside to 
achieve a low false positive rate; 
prosecution will be based on the results of 
a subsequent laboratory confirmation of 
the second sample. In the EU, while 
France uses roadside saliva tests, 
prosecution is based on the results of a 
blood test.  
Are prevention  6. 
campaigns effective?
Surveys carried out in some countries 
have revealed a lack of awareness about 
the influence of illicit drugs on driving 
ability. They also show that many drivers 
are unaware of the effects of combining 
drugs and alcohol. Among older drivers, 
awareness is often lacking of the effects of 
psychoactive medicines on driving 
performance. Furthermore, many drivers 
may be ignorant of laws prohibiting 
driving under the influence of such 
medicines.
Prevention campaigns targeting drug 
driving have been carried out in several 
EU Member States. These generally take 
the form of mass media campaigns, often 
including information on drugs within a 
wider campaign focussing on alcohol. 
General messages that reach young users 
of cannabis, however, are unlikely to be 
listened to, or even noticed, by older users 
of psychoactive medicines, and vice 
versa. Similarly, both groups may feel that 
warnings about alcohol do not apply to 
them. Prevention programmes are more 
likely to succeed if they are tailored to 
their target group.
Providing clear information to patients 
taking psychoactive medicines may 
prevent them from driving while adversely 
affected. For this, most countries rely on 
the patient information leaflet inside the 
packaging, for example advising caution 
if the patient feels sleepy. Yet the patient’s 
subjective senses are not always reliable 
or accurate. The use of a clear symbol or 
pictogram on the outer packaging of 
medicines that may affect driving ability is 
currently reported by only five countries. 
Drug driving in EU Member States may be defined as impairment caused 
by drugs or having any trace of drugs in the blood (‘zero tolerance’), and 
some countries combine both definitions in a two-tier system
Zero tolerance 
Impairment 
Two-tier system 
No information 
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Responding to drug driving in Europe:  
Conclusions and policy considerations 
1. Surveys on the prevalence of drugs in drivers need to be 
conducted in all EU Member States. Testing all drivers 
involved in a fatal accident for drug and alcohol use would 
provide an important source of information for monitoring 
the problem.
4. National laws and their enforcement need to strike a 
balance between concerns about ensuring road safety and 
the therapeutic needs of individuals.
2. New guidelines on study design are available that 
take into account the variety of legal and practical 
constraints in different countries. They aim to 
improve comparability among studies and may 
facilitate exchange of best practice.
5. Legal frameworks require review, as even with the 
limitations of existing testing methodology, more effective 
procedures are possible. And, new options are likely to 
become available. 
3. Policymakers should consider the latest scientific 
information available when designing legal responses. The 
level at which a driver will be deemed in breach of the law 
should be clear for all stakeholders and the public. 
6. Prevention campaigns should target specific risk groups 
and substances; be based on scientific evidence; and 
rigorously evaluated for impact on behaviour and attitudes.
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